More and more evidence illustrated that lncRNAs, such as Mhrt, Plscr4 and H19, could act as an important participant in the complicated network in regulating the pathological process of hypertrophy, which involves in the functional homoeostasis among sarcomere, mitochondria and intracellular calcium transition, making them as a promising target for treatment of cardiac hypertrophy. The gene discussed is PLSCR4; the disease is cardiac hypertrophy.